REG - Oxford Nanopore Tech - Issue of Equity

Oxford Nanopore TechnologiesAnnouncement

19/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240619:nRSS9063Sa&default-theme=true

RNS Number : 9063S  Oxford Nanopore Technologies plc  19 June 2024

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

FOR IMMEDIATE RELEASE

 

19 JUNE 2024

 

Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company")

 

New issue in connection with Oxford Nanopore's Long Term Incentive Plan

 

Oxford Nanopore announces that it intends to issue 11,041,901 ordinary shares
of £0.0001 each ("New Ordinary Shares") to satisfy the release of awards
under the Oxford Nanopore Technologies Limited Long Term Incentive Plan 2021
("Founder LTIP"), conditional only upon Admission (as defined below). The New
Ordinary Shares will rank pari passu with existing ordinary shares in issue.

 

Applications have been made to the Financial Conduct Authority and London
Stock Exchange for the New Ordinary Shares to be admitted to the standard
listing segment of the Official List of the Financial Conduct Authority and to
trading on the main market for listed securities of the London Stock Exchange
("Admission").

 

Admission is expected to occur at 8.00 a.m. on 21 June 2024.

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:          ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
real-time, high-performance, accessible and scalable analysis of DNA and RNA.
The technology is used in more than 120 countries to understand the biology of
humans and diseases such as cancer, plants, animals, bacteria, viruses and
whole environments. Oxford Nanopore Technologies products are intended for
molecular biology applications and are not intended for diagnostic purposes.

www.nanoporetech.com (http://www.nanoporetech.com)

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products or
accelerated adoption of pathogen surveillance. These or other uncertainties
may cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEZVLFFZQLEBBF